Featured News
April 01, 2026
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
March 12, 2026
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
Our Commitment to Responsibility
At Alkermes, we are committed to making a difference not only in the lives of people living with complex psychiatric and neurological disorders, but also in the communities in which we live and work. We seek to operate our business ethically and grow our organization in a responsible and sustainable manner. Our most recent Corporate Responsibility Report details our efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Establishing Alkermes’ Leadership in Sleep Medicine
Hear from Chief Operating Officer Blair Jackson on Alkermes’ acquisition of Avadel Pharmaceuticals plc.
World Sleep Day 2026: Sleep Well, Live Better
Michael Doane’s patient interview research deepens our understanding of the depth and breadth of the impact of narcolepsy and IH.
Honoring our 2026 HBA Luminary
Janine Shea, Alkermes’ 2026 HBA Luminary honoree, reflects on her career journey and leadership philosophy and shares advice for women building careers in life sciences.
Media Resources
Company Description
Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex, chronic psychiatric and neurological disorders. A global biopharmaceutical company headquartered in Dublin, Ireland, with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of important new medicines in areas which are often overlooked, including addiction, serious mental illness and sleep disorders.
Follow us on our social channels
